Samsung Bioepis Hit By Amgen Denosumab Lawsuit
Some Of The Patents Covering Prolia/Xgeva Are Expiring Next Year
Amgen has asserted 34 patents for alleged infringement against Samsung Bioepis, which is the highest number out of the three lawsuits filed by the originator against a denosumab biosimilar maker.
